BioLineRx (BLRX) Equity Average: 2023-2025
Historic Equity Average for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to -$396.7 million.
- BioLineRx's Equity Average fell 1.43% to -$396.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$396.7 million, marking a year-over-year decrease of 1.43%. This contributed to the annual value of -$4.6 million for FY2024, which is N/A change from last year.
- Per BioLineRx's latest filing, its Equity Average stood at -$396.7 million for Q2 2025, which was up 0.15% from -$397.3 million recorded in Q1 2025.
- In the past 5 years, BioLineRx's Equity Average ranged from a high of $6.9 million in Q4 2023 and a low of -$398.2 million during Q4 2024.
- Moreover, its 3-year median value for Equity Average was -$391.1 million (2024), whereas its average is -$298.9 million.
- Data for BioLineRx's Equity Average shows a maximum YoY plummeted of 114,056.18% (in 2025) over the last 5 years.
- BioLineRx's Equity Average (Quarterly) stood at $6.9 million in 2023, then slumped by 5,836.58% to -$398.2 million in 2024, then fell by 1.43% to -$396.7 million in 2025.
- Its last three reported values are -$396.7 million in Q2 2025, -$397.3 million for Q1 2025, and -$398.2 million during Q4 2024.